Skip to content
Dr CJC-1295

A calm, tactile reading of the CJC-1295 research record — what the GH/IGF-1 studies actually measured, where the human data stop, and how the longevity claims line up against the literature.

The paper behind each numbered note

CJC-1295 references: papers used for the study claims

This small, lab-made piece of protein was studied in people and animals. The page lists papers on blood tests, safety, aging, and related compounds.

Return to the study resultsLearn what this guide does

What each CJC-1295 paper can answer

The list below gives every CJC-1295 paper used here. Three studies from the mid-2000s followed blood tests in people [1][3][5]. They asked how high the readings rose, how long they stayed high, and which blood proteins changed. A 2005 paper asked how CJC-1295 DAC binds to albumin, the main blood-carrying protein [2].

Other papers answer nearby questions. One showed how blood breaks down the natural growth message [11]. A mouse study tracked growth [4]. Reviews cover age-linked muscle loss and how IGF-1, a liver-made growth protein, affects muscle [7][8]. Newer reviews name health and safety questions that remain open [13][14].

Use the number after a claim to find its paper here. PubMed is a public list of medical papers. A DOI is a permanent code leading to a paper online. Older papers don't always have both, and each source supports only what its study measured.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970. ↗
  8. Giovannini S, Marzetti E, Borst SE, Leeuwenburgh C. Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults. Mech Ageing Dev. 2008;129(10):593-601. ↗
  9. Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing. Oncotarget. 2016. ↗
  10. GHRH expression plasmid improves osteoporosis and skin damage in aged mice. Growth Horm IGF Res. 2021. ↗
  11. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. ↗
  12. Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men. (Early GRF(1-29) PK study; older record, registry-level identifiers pending verification.) ↗
  13. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. ↗
  14. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging. 2026. ↗
  15. (2026 peptide therapy safety review). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗
  16. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004. 363(9418):1346-1353 ↗
  17. (GH sodium-retention study). GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. ↗
  18. (GHRH analog pulsatility/insulin study). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
  19. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting - briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. ↗
  20. ConjuChem Inc. (trial sponsor). A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov. 2006. ↗
  21. Reference summary. Modified GRF (1-29) - chemical and pharmacological description. Encyclopedic reference. 2024. ↗
  22. World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA International Standard. 2025. ↗